CIQUIBIC-CONICET-UNC


  Contact : +54 351 5353855

EspañolEnglish

Second “CIQUIBIC Open Doors Lecture series”

Dr.. Annie Andrieux INSERM in Paris to speak at the lecture series organized by the CIQUIBIC
Next Wednesday 6 of May, to 11 hours, in the Auditorium of the Technological Scientific Center CONICET (CCT-Córdoba) then give the Lecture Series External Researchers "CIQUIBIC Open Doors".

In this opportunity, The conference will be headed by Dr.. Annie Andrieux, Pathophysiology lab chief of the cytoskeleton in the INSERM in Paris and the Commissariat à l'EnergieAtomique (CEA) (France).

“MAP6 proteins: from microtubules stabilization to integrated brain functions”

MAP6 proteins have been initially identified as the factor responsible for the stabilization of mammalian microtubules. MAP6 null mice exhibited synaptic defects, associated with severe behavioural defects including increased locomotor activity with purposeless and disorganized activity; severe social withdrawal; deficits in prepulse inhibition and spatial and social learning impairments. MAP6 null mice also exhibit hyper-reactivity of dopamine release associated with a hypoglutamatergic phenotype, in accordance with the dopamine/glutamate neurotransmission imbalance hypothesis in schizophrenia. Importantly, conventional and non-conventional neuroleptics alleviate behavioural and synaptic defects in STOP-null mice although differently.

MAP6 deletion leads to reduction of brain volume, mainly affecting white matter, spine density defects, and disrupts brain connectivity, with a notable absence of post-commissural fornix fibers. MAP6 contributes to fornix development by regulating axonal elongation induced by the guidance molecule Semaphorin (Sema) 3E through the binding to the Sema3E receptor complex and acts downstream receptor activation through a mechanism that requires a proline-rich domain. We show that MAP6 directly binds to SH3 domain proteins known to be involved in neurite extension and semaphorin function. Finally, epothilone D, a microtubule stabilizing drug, alleviates behavioural and synaptic defects of STOP-null mice providing experimental evidence for a role of microtubule regulation as a target of future antipsychotic agents.

Design: Jeremías Di Pietro / Graphic design CCT CONICET CORDOBA